Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ikena Oncology, Inc. Market Cap
Based on ratings from 3 stock analysts, the Ikena Oncology, Inc. stock price is expected to increase by 76.47% in 12 months. This is calculated by using the average 12-month stock price forecast for Ikena Oncology, Inc.. The lowest target is $2 and the highest is $4. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assigned IKNA 2 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Ikena Oncology, Inc. to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on IKNA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of IKNA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Andres Maldonado HC Wainwright & Co. | Buy | $4 | Reiterates | Nov 11, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $4 | Reiterates | Aug 12, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $4 | Maintains | May 29, 2024 |
| David Nierengarten Wedbush | Neutral | $2 | Downgrade | May 29, 2024 |
| David Nierengarten Wedbush | Outperform | $8 | Reiterates | May 14, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $11 | Reiterates | Mar 19, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $11 | Maintains | Mar 12, 2024 |
| David Nierengarten Wedbush | Outperform | $8 | Reiterates | Jan 19, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $11 | Reiterates | Jan 19, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $11 | Maintains | Nov 9, 2023 |
| David Nierengarten Wedbush | Outperform | $11 | Initiates | Sep 22, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $18 | Reiterates | Aug 10, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $18 | Reiterates | Aug 7, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $18 | Reiterates | May 24, 2023 |
| Judah Frommer Credit Suisse | Outperform | $13 | Reiterates | May 16, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $18 | Assumes | May 4, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $22 | Reiterates | Mar 17, 2023 |
| Judah Frommer Credit Suisse | Outperform | $13 | Maintains | Mar 15, 2023 |
| Judah Frommer Credit Suisse | Outperform | $16 | Maintains | Nov 29, 2022 |
| Robert Burns HC Wainwright & Co. | Buy | $22 | Maintains | Nov 29, 2022 |
When did it IPO
2021
Staff Count
14
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Mark Manfredi Ph.D.
Market Cap
$81.1M
In 2023, IKNA generated $9.2M in revenue, which was a decrease of -41.35% from the previous year. This can be seen as a signal that IKNA's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company reported a strong financial position with $138 million in cash and investments at the end of the third quarter.
Why It Matters - A strong cash position of $138 million indicates financial stability, flexibility for growth opportunities, and potential for shareholder returns, which can positively influence stock performance.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company reported a strong financial position with $145 million in cash and investments at the end of the second quarter.
Why It Matters - A strong cash position of $145 million indicates financial stability, allowing for potential growth investments, debt reduction, or shareholder returns, positively influencing stock performance.
Fri, 12 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - USAC, NHYDY, APOG, IKNA, and CRGY were added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024, indicating strong investment potential.
Why It Matters - Zacks Rank #1 indicates strong potential for these stocks, suggesting they may outperform the market, attracting investor interest and possibly driving up their prices.
Fri, 12 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - IKNA, AVAH, and VEL are ranked as Zacks Rank #1 (Strong Buy) momentum stocks as of July 12, 2024.
Why It Matters - IKNA, AVAH, and VEL being on the Zacks Rank #1 list indicates strong potential for price appreciation, attracting attention from bullish investors and possibly driving up demand.
Tue, 28 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ikena Oncology has discontinued the IK-930 program but continues development of IK-595 in RAS and RAF mutant cancers. The company ended Q1 with $157.3 million and is exploring strategic options.
Why It Matters - Ikena's discontinuation of IK-930 may signal a shift in focus, impacting future growth potential and investor confidence, while ongoing IK-595 development and strategic options could influence stock performance.
Tue, 28 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ikena Oncology has discontinued its IK-930 program while continuing dose escalation of IK-595 in mutant cancers. The company ended Q1 with $157.3 million and is exploring strategic options.
Why It Matters - Ikena's discontinuation of IK-930 may signal reduced growth prospects, while ongoing IK-595 development and strategic evaluations could impact future valuations and shareholder returns.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
